Global Information
회사소개 | 문의 | 비교리스트

세계의 RNAi 치료제 시장(2021-2028년)

Global RNAi Therapeutics Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품 코드 1035393
페이지 정보 영문 180 Pages
가격
US $ 4,350 ₩ 5,230,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 5,832,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 9,439,000 PDF & Excel (Enterprise License)


세계의 RNAi 치료제 시장(2021-2028년) Global RNAi Therapeutics Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 RNAi 치료제 시장 성장은 관상동맥질환, 심질환, 신경변성질환, 감염증 발생률 상승, 의약품 판매 회사와 CRO간의 공동 활동 활발화에 의해 견인되고 있습니다.

최근 FDA 의약품 승인율이 저하되고 있습니다. 신약의 FDA 승인을 얻는 것은 매우 어려워지고 있습니다. 2015년(총 45건), 2014년(총 41건)과 비교해 2016년의 신약 승인수는 절반 이하(지금까지 19건)였습니다. 그로 인해 거액의 투자에도 불구하고 제조되는 혁신적인 의약품이 감소하고 있습니다. FDA는 이 감소 추세의 주요 이유로서 제조 기준이나 기타 준수 사항을 설명하고 있습니다. 특히 miRNA와 siRNA는 비교적 새로운 유전자 의료 분야에 속하기 때문에 더 대규모의 임상시험이 필요해질 가능성이 있으며, 이것이 세계의 RNAi 치료제 시장 성장을 저해하는 요인이 되고 있습니다. 매우 광범위한 임상시험은 사실상 의약품의 낮은 승인율로 이어집니다. 따라서 엄격한 가이드라인이 시장 성장을 저해하는 큰 요인이 될 것입니다.

세계의 RNAi 치료제(RNAi Therapeutics) 시장에 대해 조사했으며, 시장 개요와 함께 종류별, 용도별, 투여 경로별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 세계의 RNAi 치료제 시장 조사 방법과 범위

  • 조사 방법
  • 조사 목적과 조사 범위

제2장 세계의 RNAi 치료제 시장 - 시장 정의와 개요

제3장 세계의 RNAi 치료제 시장 - 주요 요약

  • 종류별 시장 내역
  • 용도별 시장 내역
  • 투여 경로별 시장 내역
  • 최종사용자별 시장 내역
  • 지역별 시장 내역

제4장 세계의 RNAi 치료제 시장 - 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석

제5장 세계의 RNAi 치료제 시장 - 업계 분석

  • Porter's Five Forces 분석
  • 공급망 분석
  • 파이프라인 분석
  • 가격 분석
  • 규제 분석
  • 미충족 수요
  • 특허 분석

제6장 세계의 RNAi 치료제 시장 - COVID-19 분석

  • 시장에서의 COVID-19 분석
    • COVID-19 이전 시장 시나리오
    • COVID-19 현재 시장 시나리오
    • COVID-19 이후 또는 향후 시나리오
  • COVID-19의 가격 역학
  • 수요와 공급 스펙트럼
  • 팬데믹 동안 시장과 관련된 정부 정책
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 RNAi 치료제 시장 - 종류별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 종류별
    • 시장 매력 지수
  • 저분자 간섭 RNA(siRNA)
    • 서론
    • 시장 규모 분석, 백만 달러, 2018-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 마이크로 RNA(miRNA)

제8장 세계의 RNAi 치료제 시장 - 용도별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용도별
    • 시장 매력 지수
  • 종양학
    • 서론
    • 시장 규모 분석, 백만 달러, 2018-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 심혈관
  • 호흡기질환
  • 신장질환
  • 유전성 질환
  • 신경변성질환
  • 감염증
  • 기타

제9장 세계의 RNAi 치료제 시장 - 투여 경로별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 투여 경로별
    • 시장 매력 지수
  • 경폐 전달
    • 서론
    • 시장 규모 분석, 백만 달러, 2018-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 정맥주사
  • 피내주사
  • 복강내주사
  • 기타

제10장 세계의 RNAi 치료제 시장 - 최종사용자별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 매력 지수
  • 병원
    • 서론
    • 시장 규모 분석, 백만 달러, 2018-2028년 및 전년대비 성장 분석(%), 2020-2028년
  • 연구·학술 연구소
  • 진단 연구소

제11장 세계의 RNAi 치료제 시장 - 지역별

  • 서론
    • 시장 규모 분석, 백만 달러, 2018-2028년 및 전년대비 성장 분석(%), 2020-2028년, 지역별
    • 시장 매력 지수
  • 북미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용도별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 투여 경로별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 유럽
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용도별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 투여 경로별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 남미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용도별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 투여 경로별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 아시아태평양
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용도별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 투여 경로별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 국가별
  • 중동과 아프리카
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%), 종류별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 용도별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 투여 경로별
    • 시장 규모 분석 및 전년대비 성장 분석(%), 최종사용자별

제12장 세계의 RNAi 치료제 시장 - 경쟁 상황

  • 경쟁 시나리오
  • 주요 발전과 전략
  • 기업 점유율 분석
  • 제품 벤치마크
  • 주목해야 할 주요 기업
  • 파괴적 기술을 보유한 기업

제13장 세계의 RNAi 치료제 시장 - 기업 개요

  • Alnylam Pharmaceuticals, Inc
    • 기업 개요
    • 제품 포트폴리오와 개요
    • 주요 하이라이트
    • 재무 개요
  • Dicerna Pharmaceuticals
  • Silence Therapeutics
  • Arrowhead Pharmaceuticals, Inc
  • Sanofi
  • Glaxosmithkline Plc
  • Arbutus Biopharma Corporation
  • Benitec Biopharma
  • Thermo Fisher Scientific Inc
  • Sirnaomics, Inc

제14장 세계의 RNAi 치료제 시장 - DataM

  • 부록
  • 당사·서비스에 대해
  • 문의
KSM 21.11.16

Market Overview

The global RNAi therapeutics market size was worth US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).

RNA therapeutics are a novel class of medications based on ribonucleic acid (RNA). RNA interference is a biological process in which target mRNA molecules are neutralized, and RNA molecules are observed to inhibit gene expression or translation. Furthermore, RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequential-specific inhibition of genetic expression.

Market Dynamics

The global RNAi therapeutics market growth is driven by the increasing incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases, increasing collaborative activities between drug distribution companies and contract research organizations (CROs).

Increasing collaborative activities boosting the growth of RNAi therapeutics market

The increasing collaborative activities between drug distribution companies and contract research organizations (CROs) contribute to RNAi therapeutics market growth. In June 21, 2021, Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and license agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout. This collaboration with Horizon also represents further expansion of Arrowhead Pharmaceuticals rapidly growing pipeline of investigational RNAi therapeutics that utilize Arrowhead's proprietary Targeted RNAi Molecule (TRiMTM) platform." In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) initiated a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to the treatment of Hepatitis B viral infection. And also, one more collaboration by Ionis pharmaceuticals with Akcea Therapeutics has led to the approval of the world's first antisense-based molecule "Tegsdi" by the FDA and the European Commission in 2018.

Moreover, despite these factors it has a potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies. Quark, Alnylam and silence therapeutics are other major players of this market with strong research pipeline in RNAi therapeutics. For instance, Silence therapeutics mRNAi GOLD platform is designed to deliver gene silencing medicine to targeted liver cells in the body by combining siRNA molecules with chemical address tags called GaINAc, a naturally occurring sugar that attaches specifically to liver cells. These RNAi molecules can then enter liver cells and silence targeted; disease-associated genes expressed in the liver.

In May 2021, Silence therapeutics completed its phase 1 study of SLN124, is a gene silencing therapy for treating rare iron-loading anemia conditions, thalassemia and myelodysplastic syndrome (MDS) patients.

High investment and strict regulations are likely to hamper the market growth

In recent years, there has been a decline in FDA drug approval rates. Receiving FDA approval for a new drug has become extremely challenging. It approved less than half the number of new drugs in 2016 (19 so far) when compared to 2015 (45 total) and 2014 (41 total). Hence, despite the large investments, there has been a decline in innovative drugs manufactured. FDA explains manufacturing standards and other complying issues as the major reasons for this declining trend. This can impede the growth of the RNAi therapeutics, especially since the miRNAs and siRNAs fall into the relatively new field of genetic medicine, wherein they may require more intensified clinical trials. The highly extensive clinical trials effectively result in low approval rates of drugs. This would mean that the stringent guidelines will be a major restraint on the growth of the market.

COVID-19 Impact Analysis

There has been continuous progress in understanding diseases at the genomic and molecular levels, and various companies are deploying resources to test these diseases to leverage opportunities that fuel the market opportunities. For instance, in August 2020, GeneDx Inc., a subsidiary of BioReference Laboratories Inc., and OPKO Health agreed with Pediatrix Medical Group to offer state-of-the-art, next-generation genomic sequencing to support the clinical diagnosis of rare diseases for neonatal intensive care units.

RNAi has been widely accepted in providing the highest possible resolution information about COVD-19 and is believed to potentially transform COVID-19 infectious disease management.

For instance, in earlier 2020, the UK government launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. The COVID-19 Genomics UK Consortium (COG-UK) comprises the NHS (National Health Service), public health agencies, the Wellcome Sanger Institute, and several academic institutions, helping in creating funds and developing diagnostics and treatment.

Segment Analysis

The oncology segment is expected to hold the largest share in this market segment

According to the World Health Organization, cancer is the second leading cause of death globally and responsible for 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. The number of new cases is expected to increase by about 70% over the next two decades. Also, recent advancements, such as the development of small interfering RNA (siRNA) tolerant to nucleases and non-viral vectors, such as cationic liposomes and nanoparticles, can overcome this obstacle and facilitate the clinical use of RNAi-based therapeutics in the treatment of cancer.

Substantial pipeline for cancer therapies by companies and institutes such as Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, AstraZeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. are expected to drive the market. In addition, many companies have invested in R&D for nanocarriers to deliver oligonucleotides for cancer treatment, which is expected to contribute to the oncology segment.

Geographical Analysis

North America region holds the largest market share of global RNAi therapeutics market

The U.S. has several RNAi therapies that are in the developmental pipeline. Many biotechnology companies have invested heavily in RNAi therapeutic development. Many pharmaceutical developers have entered into cooperation agreements or licensing agreements with many small companies to capitalize on the expected growth in revenue during the forecast period of this market. For example, AstraZeneca's deal with Ionis Pharmaceuticals is majorly investing heavily in RNA-interference technology. Also, in September 2018, Delos Capital developed MRNA-based drugs for chemotherapy-resistant cancer. Curamir Therapeutics received initial financial support. With the help of these new companies, acquisitions, and new inventions, North America is dominating the market.

Competitive Landscape

The global RNAi therapeutics market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Silence Therapeutics, Arrowhead Pharmaceuticals, Inc, Sanofi, Glaxosmithkline Plc, Arbutus Biopharma Corporation, Benitec Biopharma, Thermo Fisher Scientific Inc and Sirnaomics, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, on April 8, 2019, Regeneron Pharmaceuticals, Inc and Alnylam Pharmaceuticals, Inc announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies' scientific and technological expertise and will build on Alnylam's recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS.

Global RNAi Therapeutics Market - Key Companies to Watch

Alnylam Pharmaceuticals, Inc

  • Overview: Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. It operates in 19 countries with more than 1K employees. It conducts its operations in RNAi (RNA interference) from Nobel Prize-winning discovery into an entirely new class of medicines. In 2018, its first medicine, ONPATTRO (patisiran), became the world's first approved RNAi therapeutic. They are advancing a robust pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
  • Product Portfolio: It include products like ONPATTRO (patisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran).
  • Key Developments: Alnylam Pharmaceuticals, ALN-HBV02 is a subcutaneously administered, investigational RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of chronic HBV infection. ALN-HBV02 is designed to inhibit expression of all HBV proteins, including hepatitis B surface antigen (HBsAg) is under Phase 3 trials. ALN-HBV02 utilizes the Enhanced Stabilization Chemistry-Plus (ESC+)-GalNAc delivery platform.

Global RNAi Therapeutics Market - Notable Developments

In November 2017, Arcturus Therapeutics merged with Alcobra Ltd.

In October 2017, Alnylam and Vir formed a strategic alliance to advance RNAi therapeutics for infectious diseases.

On February 26, 2020, Alnylam Pharmaceuticals, Inc. RNAi Therapeutics, a leading company has announced that the Brazilian Health Regulatory Agency (ANVISA) has approved ONPATTRO for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

June 2020, OliX Pharmaceuticals entered into an agreement with LGC Biosarch Technology to accelerate the production of asymmetric siRNA for the treatment of sub-retinal fibrosis and wet macular degeneration.

Why Purchase the Report?

  • Visualize the composition of the RNAi therapeutics market segmentation by type, application, end-user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in RNAi therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of RNAi therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players.

The global RNAi therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global RNAi Therapeutics Market - By Type

  • Small Interfering RNAs (siRNA)
  • ONPATTRO
  • GIVLAARI
  • OXLUMO
  • Others
  • MicroRNA (miRNA)

Global RNAi Therapeutics Market - By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others

Global RNAi Therapeutics Market - By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others

Global RNAi Therapeutics Market - By End-User

  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories

Global RNAi Therapeutics Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global RNAi Therapeutics Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global RNAi Therapeutics Market - Market Definition and Overview

3. Global RNAi Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by End-User
  • 3.5. Market Snippet by Region

4. Global RNAi Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing collaborative activities
    • 4.1.2. Restraints:
      • 4.1.2.1. High investment and strict regulations
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global RNAi Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pipeline Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis

6. Global RNAi Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global RNAi Therapeutics Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Small Interfering RNAs (siRNA)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
      • 7.2.2.1. ONPATTRO
      • 7.2.2.2. GIVLAARI
      • 7.2.2.3. OXLUMO
      • 7.2.2.4. Others
  • 7.3. MicroRNA (miRNA)

8. Global RNAi Therapeutics Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Oncology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Cardiovascular
  • 8.4. Respiratory Disorders
  • 8.5. Renal Diseases
  • 8.6. Genetic Disorders
  • 8.7. Neurodegenerative Disorders
  • 8.8. Infectious Diseases
  • 8.9. Others

9. Global RNAi Therapeutics Market - By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Pulmonary Delivery*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Intravenous Injections
  • 9.4. Intradermal Injections
  • 9.5. Intraperitoneal Injections
  • 9.6. Others

10. Global RNAi Therapeutics Market - By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
    • 10.1.2. Market Attractiveness Index, By End-User Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Research and Academic Laboratories
  • 10.4. Diagnostic Laboratories

11. Global RNAi Therapeutics Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

12. Global RNAi Therapeutics Market - Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Key Developments and Strategies
  • 12.3. Company Share Analysis
  • 12.4. Product Benchmarking
  • 12.5. Key Companies to Watch
  • 12.6. Company with disruptive technology

13. Global RNAi Therapeutics Market- Company Profiles

  • 13.1. Alnylam Pharmaceuticals, Inc*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Dicerna Pharmaceuticals
  • 13.3. Silence Therapeutics
  • 13.4. Arrowhead Pharmaceuticals, Inc
  • 13.5. Sanofi
  • 13.6. Glaxosmithkline Plc
  • 13.7. Arbutus Biopharma Corporation
  • 13.8. Benitec Biopharma
  • 13.9. Thermo Fisher Scientific Inc
  • 13.10. Sirnaomics, Inc (LIST NOT EXHAUSTIVE)

14. Global RNAi Therapeutics Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us
Back to Top
전화 문의
F A Q